Ceasefire extension, Best Buy's new CEO, Amazon's GLP-1 push and more in Morning Squawk

Trump extended the Iran ceasefire, but reports of ship seizures and attacks in the Strait of Hormuz keep geopolitical and oil-market risks elevated. Boeing and United Airlines posted better-than-expected quarterly results, while Best Buy named insider Jason Bonfig as its next CEO and Amazon expanded access to GLP-1 drugs through One Medical and Amazon Pharmacy. Kevin Warsh faced a contentious Fed confirmation hearing, and Trump also signaled he may remember companies that do not seek tariff refunds.

Analysis

The cleanest read-through is that markets are pricing a de-escalation premium faster than the physical oil market can validate it. If the Strait of Hormuz remains intermittently disrupted, the front end of the curve can reprice sharply even while equities try to fade geopolitical risk; that disconnect usually benefits energy vol more than directional oil beta. The second-order trade is that airlines and other fuel-sensitive balance sheets are not just facing higher input costs, but also a demand risk if consumers interpret persistent oil spikes as a broad inflation shock.

Boeing’s better-than-feared print matters less as a single quarter than as evidence that execution risk is becoming less asymmetric. If delivery confidence improves, the stock can rerate on reduced left-tail risk even without a step-function in end-market demand; the more interesting knock-on is pressure on peers and suppliers if capital begins rotating toward names with visible near-term cash conversion. United’s guidance cut underscores that margin compression from fuel is arriving before any network pricing benefits, which typically forces domestic carriers to compete harder on fare stimulation into a weaker earnings backdrop.

Amazon’s GLP-1 push is a margin-and-distribution story, not just a pharmacy expansion. The company is effectively trying to compress the last-mile friction that has protected specialty channels, which can pressure pure-play digital health distributors first and then force branded obesity-drug incumbents to spend more on patient retention. The market seems to be underestimating how quickly Amazon can bundle refill, telehealth, and delivery into a lower-churn funnel; that is structurally negative for intermediaries with weaker logistics and higher customer acquisition costs.

On the consumer side, Best Buy’s management transition is less about continuity than whether the new CEO can use AI-refresh cycles to pull demand forward into a weak replacement cycle. If AI-enabled devices do not drive a meaningful upgrade wave in the next 2-3 quarters, BBY risks becoming a price-taker in a low-growth category. The broader setup is a bifurcation: logistics-heavy incumbents with scale can win share, while smaller healthcare and retail intermediaries face margin compression from platform entrants and supply-chain leverage.

Key Decisions for Investors

• Long AMZN vs short HIMS into the next 1-3 months: Amazon’s logistics and refills can compress specialty pharmacy economics; downside on HIMS is highest if prescription acquisition costs rise or reimbursement friction persists.
• Buy BA on pullbacks with a 6-12 week horizon, but finance it against UAL or another fuel-sensitive carrier: Boeing has improving execution optionality, while airlines still face near-term margin erosion if oil volatility persists.
• Short UAL into oil spikes via call spreads or outright stock, 2-8 weeks: the risk/reward skews negative because earnings revisions typically lag fuel shocks by a quarter, while demand elasticity can compound the hit later.
• Pair long BBY / short a weaker consumer electronics peer basket for 3-6 months: if AI upgrade demand materializes, scale and vendor leverage should concentrate share with the largest retailer first.
• Optionality trade: long AMZN calls or call spreads into the next GLP-1 adoption data window, with a 3-6 month horizon; upside comes from pharmacy cross-sell and delivery monetization, while risk is limited to execution delays rather than thesis breakage.